Open access
Sep 2026
Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors
Background: Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy. Methods: We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI...
H. Karakaş, S. C. Efil, B. Bilgin et al.
· Current Oncology · 0 citations